Brokerages Set Oruka Therapeutics, Inc. (NASDAQ:ORKA) Target Price at $39.86

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have earned an average recommendation of “Buy” from the nine ratings firms that are currently covering the stock, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $39.86.

Several equities analysts have recently weighed in on ORKA shares. HC Wainwright reissued a “buy” rating and issued a $45.00 price objective on shares of Oruka Therapeutics in a research report on Friday, February 7th. Wedbush reissued an “outperform” rating and issued a $40.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, November 19th. Finally, Wolfe Research assumed coverage on shares of Oruka Therapeutics in a research note on Tuesday, February 4th. They issued an “outperform” rating and a $20.00 price target on the stock.

Oruka Therapeutics Price Performance

Shares of ORKA opened at $10.76 on Friday. The company has a market capitalization of $376.60 million, a price-to-earnings ratio of -1.72 and a beta of 0.77. The company has a 50-day moving average of $15.82. Oruka Therapeutics has a fifty-two week low of $10.61 and a fifty-two week high of $53.88.

Institutional Investors Weigh In On Oruka Therapeutics

A number of large investors have recently bought and sold shares of the company. JPMorgan Chase & Co. acquired a new stake in Oruka Therapeutics during the fourth quarter worth about $54,000. AlphaCentric Advisors LLC acquired a new stake in Oruka Therapeutics during the fourth quarter worth about $119,000. China Universal Asset Management Co. Ltd. acquired a new stake in Oruka Therapeutics during the fourth quarter worth about $144,000. Squarepoint Ops LLC acquired a new stake in Oruka Therapeutics during the fourth quarter worth about $236,000. Finally, Wellington Management Group LLP grew its stake in Oruka Therapeutics by 15.8% during the fourth quarter. Wellington Management Group LLP now owns 95,089 shares of the company’s stock worth $1,844,000 after buying an additional 12,952 shares in the last quarter. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.